Suppr超能文献

使用新型二苯并噻嗪光敏剂对动物自然发生的肿瘤进行光动力治疗。

Photodynamic therapy of naturally occurring tumors in animals using a novel benzophenothiazine photosensitizer.

作者信息

Frimberger A E, Moore A S, Cincotta L, Cotter S M, Foley J W

机构信息

The Harrington Oncology Program, Tufts University School of Veterinary Medicine, North Grafton, Massachusetts 01536, USA.

出版信息

Clin Cancer Res. 1998 Sep;4(9):2207-18.

PMID:9748141
Abstract

5-Ethylamino-9-diethylaminobenzo[a]phenothiazinium chloride (EtNBS) is a novel photodynamic therapy (PDT) photosensitizer with efficacy against experimental murine tumors. In this preliminary study, dogs and cats with naturally occurring tumors were treated with EtNBS-PDT to determine safety and efficacy. Fifteen treatments were performed on 13 animals (9 treatments in 8 cats and 6 treatments in 5 dogs), generally using 400 J of 652 nm light. Two feline sublingual squamous cell carcinomas (SCCs) responded briefly (minor response). Six feline facial SCCs were treated, resulting in two partial responses and four long-term complete responses (CR). Two canine intraoral SCCs were treated; one responded minimally for 2 weeks (minor response), and one achieved long-term CR. One canine cutaneous mast cell tumor achieved CR, and one canine ocular mast cell tumor responded briefly. One canine ocular melanoma did not respond to treatment. Systemic reactions included nausea associated with photosensitizer injection in two cats and two dogs, elevated body temperatures during treatment in two dogs, elevated body temperature 2 days after PDT in one cat, and inappetance for 2 weeks in one cat. A peripheral neuropathy of undetermined cause occurred in one cat 2 weeks after PDT and resolved without treatment. Local reaction was well tolerated in 13 of 15 treatments. All animals were exposed to normal daylight after less than 5 days (mean, 3.5 days) without residual photosensitization. EtNBS-PDT is safe for dogs and cats and has activity against selected naturally occurring tumors, with an overall objective response rate (partial response + CR) of 61.5%.

摘要

5-乙基氨基-9-二乙氨基苯并[a]吩噻嗪鎓氯化物(EtNBS)是一种新型光动力疗法(PDT)光敏剂,对实验性小鼠肿瘤有效。在这项初步研究中,对患有自然发生肿瘤的犬猫进行了EtNBS-PDT治疗,以确定其安全性和有效性。对13只动物进行了15次治疗(8只猫接受了9次治疗,5只狗接受了6次治疗),一般使用400 J的652 nm光。两只猫的舌下鳞状细胞癌(SCC)有短暂反应(轻微反应)。对6只猫面部SCC进行了治疗,产生了2例部分缓解和4例长期完全缓解(CR)。对2例犬口腔SCC进行了治疗;1例有2周的轻微反应,1例实现了长期CR。1例犬皮肤肥大细胞瘤实现了CR,1例犬眼肥大细胞瘤有短暂反应。1例犬眼黑色素瘤对治疗无反应。全身反应包括2只猫和2只狗注射光敏剂后出现恶心,2只狗治疗期间体温升高,1只猫PDT后2天体温升高,1只猫食欲不振2周。1只猫在PDT后2周出现原因不明的周围神经病变,未经治疗自行缓解。15次治疗中有13次局部反应耐受性良好。所有动物在不到5天(平均3.5天)后暴露于正常日光下,无残留光敏反应。EtNBS-PDT对犬猫安全,对某些自然发生的肿瘤有活性,总体客观缓解率(部分缓解+CR)为61.5%。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验